Compare CRWD & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWD | TMO |
|---|---|---|
| Founded | 2011 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5B | 164.3B |
| IPO Year | 2019 | 1996 |
| Metric | CRWD | TMO |
|---|---|---|
| Price | $675.25 | $464.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 48 | 18 |
| Target Price | $507.00 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 3.2M | 2.1M |
| Earning Date | 06-02-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | 0.11 | ★ 4.43 |
| Revenue | $4,812,005,000.00 | ★ $20,918,000,000.00 |
| Revenue This Year | $24.85 | $6.55 |
| Revenue Next Year | $21.40 | $5.11 |
| P/E Ratio | $6,180.45 | ★ $103.84 |
| Revenue Growth | ★ 21.71 | 14.47 |
| 52 Week Low | $342.72 | $390.50 |
| 52 Week High | $785.66 | $643.99 |
| Indicator | CRWD | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 46.81 |
| Support Level | $456.60 | $456.87 |
| Resistance Level | $785.66 | $494.30 |
| Average True Range (ATR) | 35.67 | 12.37 |
| MACD | -10.31 | -0.99 |
| Stochastic Oscillator | 37.10 | 20.73 |
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).